Cite
HARVARD Citation
Reardon, D. et al. (n.d.). Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma. Neuro-oncology. 17 (3), pp. 430-439. [Online].